Bone Therapeutics traite le premier patient de l’étude de Phase IIb évaluant ALLOB dans les fractures du tibia
12 janv. 2021 01h00 HE
|
Bone Therapeutics SA
INFORMATION REGLEMENTEE Fin du recrutement des patients attendue au premier semestre 2022 Résultats principaux de l’étude attendus au second semestre 2022 Gosselies, Belgique, 12...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
15 déc. 2020 08h30 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
07 déc. 2020 16h05 HE
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Long-term Clinical Benefit and...
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
23 nov. 2020 08h30 HE
|
ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
07 oct. 2020 08h30 HE
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
08 déc. 2019 16h00 HE
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for...
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
10 mai 2019 08h00 HE
|
uniQure Inc.
~ Increases in FIX Activity Sustained at up to 57% of Normal, with Mean FIX of 47% of Normal at Six Months After Administration ~ ~ None of the Patients Received Factor Infusions or Reported...
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
08 févr. 2019 07h00 HE
|
uniQure Inc.
~ Increases in FIX Activity Sustained at up to 51% of Normal, with Mean FIX of 38% of Normal at Twelve Weeks After Administration ~ ~ None of the Patients Received Factor Infusions, Reported Bleeding...
uniQure to Participate in Multiple Upcoming Industry Conferences
30 janv. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
15 nov. 2018 07h00 HE
|
uniQure Inc.
~ All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31% of Normal at Six Weeks After Administration ~ ~ None of the Patients Received Factor Infusions,...